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Abstract  
Advances in genomic medicine are improving diagnosis and treatment of some health conditions, 
and the question of whether former patients should be recontacted is therefore timely. The issue of 
recontacting is becoming more important with increased integration of genomics in ‘mainstream’ 
medicine.  
Empirical evidence is needed to advance the discussion over whether and how recontacting should 
be implemented. We administered a web-based survey to genetic services in European countries  
to collect information about existing infrastructures and practices relevant to recontacting patients.  
The majority of the centres stated they had recontacted patients to update them about new 
significant information; however, there were no standardised practices or systems in place. There 
was also a multiplicity of understandings of the term ‘recontacting’, which respondents conflated 
with routine follow-up programs, or even with post-test counselling. 
Participants thought that recontacting systems should be implemented to provide the best service to 
the patients and families. Nevertheless, many barriers to implementation were mentioned. These 
included: lack of resources and infrastructure, concerns about potential negative psychological 
consequences of recontacting, unclear operational definitions of recontacting, policies that prevent 
healthcare professionals from recontacting, and difficulties in locating patients after their last 
contact. These barriers are also intensified by the highly variable development (and establishment) 
of the specialties of medical genetics and genetic counselling across different European countries. 
Future recommendations about recontacting need to consider these barriers. It is also important to 
reach an ‘operational definition’ that can be useful in different countries. 
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Introduction 
 
The question about whether healthcare professionals (HCPs) should recontact patients if new 
genetic information becomes available is becoming more pressing as large scale genomic 
collections facilitate new interpretations more frequently [1-4]. A systematic review on recontacting 
conducted by Otten et al.[5] highlighted that the question about recontacting has become more 
important after the introduction of next-generation sequencing, and the concomitant increase in 
Variants of Unknown Significance (VUSs). Otten et al. define recontacting as the HCPs’ potential 
“ethical and/or legal obligation to recontact former patients in light of new genetic information”.  
The use of the word ‘former’ implies that patients have previously been discharged from care, but 
we acknowledge that the question about recontacting can arise even without a formal discharge 
(depending on the service, e.g. general practitioners tend not to discharge patients) if a long period 
of time has elapsed. 
The literature tends to view recontacting as ethically desirable even if currently it is not the standard 
of care. Nevertheless, there are arguments both in favour and against recontacting. On one hand, 
recontacting is seen as potentially benefiting the health and psychological wellbeing of patients and 
their relatives. However there are also concerns about the psychosocial complexity of recontacting 
[6], including the concern that it may be experienced by patients as an intrusion of privacy, a breach 
of their right not to know [7],  as a cause of anxiety and stress, also any impact in relation to health 
and life insurance [1, 8, 9]. Practical issues such as lack of time, dedicated staff, resources and 
infrastructure to reliably track patients are also often mentioned as important barriers to 
recontacting [10-13].  
A survey of  regulations and practices of genetic counselling in 38 European countries, highlighted 
that recontacting is one of the least covered topics in both professional guidelines and national 
policies [14]. To date, there is only one set of professional guidelines specifically addressing 
recontacting and these are from the USA [2]. This holds the primary care physician responsible for 
alerting patients about the potential need for recontacting because genetic services often do not 
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maintain an on-going relationship with the patients. The 2008 revision [15] of this guideline 
recommends  that any clinical genetic laboratory scientist who becomes aware of new information 
should make an effort to alert the referring physician if  the clinical interpretation of a genetic 
finding changes. However, this may not always be an easy task for the laboratory, due to lack of 
time and resources. The problem is further complicated by the fact that– as genetic testing is 
increasingly offered by specialties other than clinical genetics (e.g. cardiology, oncology, 
neurology), in so-called mainstream medicine [16] – the referring physician is sometimes difficult 
to identify. 
HCPs and patients interviewed in the UK both expressed concerns about the feasibility of routine 
recontacting within current resource constraints, but also about a lack of clarity over roles and 
responsibilities [4, 6].  Some authors have suggested that patients could take an active part by 
requesting updates from their clinicians [17, 18]. However, the idea of sharing responsibility with 
patients could amplify existing health and social inequalities. For example, more educated, 
articulate and assertive patients might seek updates from HCPs much more often than less educated 
or assertive patients, whose needs might be greater [19]. Besides, ‘autonomy’ is one of the tenets in 
genetic counselling, and we have to consider that patients can autonomously choose to not seek 
updates.    
More empirical evidence is needed to advance the discussion over whether and how recontacting 
should be implemented; however, such evidence is still sparse. Carrieri et al.[20] surveyed clinical 
genetic centres in the UK regarding their recontacting practices and attitudes. Twenty of twenty-
four UK centres responded to this survey. The majority indicated that recontacting patients and 
family members was appropriate if there was some clinically relevant new information. However, 
the survey highlighted that there are no standard recontacting practices in the UK and most centres 
were unsure whether systematic recontacting should be implemented. Many expressed concerns 
about such implementation, for example fear of being viewed as negligent if they failed to 
recontact.  To provide more empirical data on current recontacting practices, we administered the 
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UK survey to genetic centres in Europe.  
Method 
The main objective of the survey was to ascertain whether and how recontacting occurs in clinical 
genetic centres in Europe. We chose to use the same questions as in the UK survey [20] to combine 
the data gathered in the UK with the other European countries.  
The survey was administered between August 2016 and April 2017. A link to the survey was 
circulated via an e-mail invitation to the President or the contact person of the National Human 
Genetic Societies listed on the ESHG webpage: https://www.eshg.org/76.0.html. In some countries, 
the National Human Genetic Societies circulated the survey to their genetic centres. In other 
countries, the National Human Genetic Societies provided a list of the genetic centres or contact 
persons and we circulated the survey directly to the named clinical genetic centres referred. For 
several countries it was impossible to find or to construct a complete list or the number of the 
clinical genetic centres. We also asked the presidents of the National Societies about the number of 
centres in their own country, but for most countries we did not receive a clear answer (some of 
these societies were in the process of undertaking a ‘census’ of clinical genetics centres in their 
country). For instance, in some countries, genetic counselling can be performed by biologists or 
physicians whose main occupation is to work in a small laboratory and who only rarely perform 
patient counselling. Moreover, in some countries the residency program in medical genetics is still 
not developed and there is a lack of medical geneticists and genetic counsellors.  
The professional role of respondents were diverse, and included Head of the service, genetic 
counsellor, consultant, and trainee. However, we wanted respondents to complete the survey on 
behalf of their whole service. To encourage this, we asked respondents (both in the introduction to 
the survey and in the accompanying email) to discuss the survey questions with their colleagues 
before filling it in. 
The survey included closed and open questions with expandable text boxes to elicit explanatory 
comments and examples. This combination of closed and open questions allowed the research team 
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to collect both quantitative and qualitative data. Free-text responses from the survey were analysed 
using content analysis – using the survey questions as a framework to categorise the answers. 
Quantitative closed questions were analysed using descriptive statistics. The data was initially 
analysed by FS and DC. The analysis was further developed involving the other authors via face-to-
face meetings (organised by the ESHG PPPC between 2016 and 2017) and several iterations of 
comments on drafts of the paper. The survey is provided as Supplementary Information.  
 
 
Results 
 
[Figure 1] 
 
Among the 105 genetic centres that answered the survey, 100 stated that they had recontacted 
patients or families to update them about new significant information. See table 1 for a summary of 
the reasons given. However, only 37 affirmed that they recontact routinely, and 63 indicated that 
they recontact on an occasional basis. 
 
[Table 1] 
    
Among the 5 genetic centres that stated they had not recontacted patients, 3 indicated that this was 
due to insufficient staff and/or resources; one reported that the policy in their country does not 
allow a direct recontacting of the patients; and one indicated that this was due to the absence of 
recontacting procedures. 
It is worth noting that some centres did not differentiate routine follow-up (e.g. discussing at 
subsequent and more appropriate times the complications of a patient’s condition, or periodical pre-
arranged appointments) from recontacting a previously discharged patient in light of new 
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information. Some respondents referred to recontacting as being a process that can also be initiated 
by the patient (e.g. when new information comes from the proband or his/her family) or support 
groups (e.g. when the patient is invited to clinical meetings or support group meetings). In some 
cases, the responses of one centre combined more than one of these understandings of the term 
recontacting.  
 
Situations in which recontacting is considered good clinical practice 
The answers to the question about the type of information the genetic centres considered relevant 
enough to trigger a recontact were coherent with the reasons given for having recontacted patients 
(summarised in Table 1). Recontacting was considered important, and patients tended to be 
recontacted, in the light of new, clinically relevant information: 
 
“We consider it relevant to trigger recontact when there is availability of new treatment 
strategies/options, (including new phase 2-3 trials),  new testing strategies, new information 
that may have impact on family planning and reproductive options and  any new 
information that may have impact on follow-up of a patients  (e.g. cancer susceptibility)” 
 
Recontacting procedures 
Among the 100 centres that responded that they recontacted patients, 41 stated they had developed 
recontacting procedures, and 59 stated they had not developed them. Within both groups, there were 
centres that affirmed they recontacted routinely and occasionally. 
The procedures reported varied across and within countries and the majority of the centres used 
more than one method. The procedures are summarised in table 2, and some examples are provided 
with quotations below: 
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“Patients attended in our hospital have signed an IC [informed consent] accepting or 
refusing to be recontacted and we follow their decisions” 
 
“We contact the patient and mention the reason for the call briefly. If they do not accept, we 
mark the patient file accordingly. We ask them if they do not want to be contacted by our 
institution. If the answer is no, we again mark it on the file as ‘do not call the patient 
again’” 
 
[Table 2] 
A minority of respondents (3) mentioned also the role of the laboratory in the recontact procedure 
(e.g. they stated that the clinical team received updates from the laboratory). 
 
Use of databases for recontacting purposes  
84 centres stated that they used a database for recontacting purposes. Among these, 56 indicated 
that they use databases for both demographics (to access patient’s contact details) and clinical 
genetic purposes (e.g., link the patient with other relatives’ records, access laboratory results, access 
and review medical notes, flag/unflag patients). 23 reported their use of databases only for 
demographic purposes. 5 centres did not specify in which ways they use databases for recontacting. 
The way databases were used for recontacting appeared to vary considerably across and within 
countries. This seemed to be mostly the result of the different programs/software packages used.  
Furthermore, respondents’ answers suggested that most of the existing databases were not easily 
usable for recontacting purposes e.g. they did not allow the recording of patient recontacting 
preferences (which appeared to be recorded instead on paper in the patient file).  
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“We use databases to find patients with the relevant condition and get their contact details; 
occasionally we flag them for future recontact but this is limited currently, though we may 
expand it when our new database is working (is currently being implemented)” 
 
“Not one database in use contains all information and is suitable for this purpose. Several 
databases are being used (e.g. a cardiogenetic database from the lab as well as a clinical 
database). It is always a struggle to identify patients on characteristics like mutation, gene, 
disease etc.” 
Assessing and recording patient recontacting preferences  
A majority of services (70) indicated that they record patient’s recontacting preferences.  
Of these, 35 stated that they systematically ask patients about their recontacting preferences. A 
large majority of these (31/35) indicated that this was part of the procedure for obtaining informed 
consent for genetic testing.  The other 35 services responded that they asked patients about their 
recontacting preferences only occasionally; and a minority of these (14/35) did it as part of the 
procedure for obtaining informed consent for genetic testing. 
A small minority (5/35) of the genetic centres that did not record patient recontacting preferences, 
reported that they asked patients about their recontacting preferences on the informed consent form 
for genetic testing. 
The recording of patients’ recontacting preferences varied considerably (e.g. some centres recorded 
patients’ preferences only if patients asked not to be recontacted, whilst others systematically 
recorded any preference). A minority of the centres that declared they record patients’ preferences 
systematically or occasionally stated that they did not ask that in the consent form. Some explained 
that they ask about the patients’ preference in conversation and record this in the patient file.  
 “If the patient states that he wants to be recontacted we pay attention and put alerts for it.  
Most of the time people love to be recontacted. They feel better. They feel that a health 
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professional is caring for them. They feel secure. In our country most of the patients get very 
happy if they are recontacted by a physician.” 
 
“We get a written consent at the first contact, but we don't ask patients directly whether they 
wish to be recontacted.” 
 
The majority of the services that said that they did not assess or record their patients’ recontacting 
preferences stated that this was mainly due to a lack of resources available to offer a recontacting 
service. Some also expressed a concern about raising unrealistic expectations in patients, including 
fear of potential litigations. 
 
“When you discuss recontact with your patient you are probably raising expectations. At 
this moment, we are unsure we will be able to deliver on those expectations” 
 
Many services, both those that ask and do not ask about patient preferences, mentioned that they 
have an ‘open-door policy’, i.e. HCPs encourage patients to get back in touch with the genetics 
department to check if there are advances and/or to update HCPs about important changes in the 
family. 
Some respondents justified not recording patients’ recontacting preferences in their centres by 
commenting that, in their experience, patients had never or rarely expressed a desire not to be 
recontacted.    
 
 “It rarely happens that a patient asks not to be recontacted, so we do not ask it as a routine.   
It is more likely that some patients refuse the possibility to continue with further evaluations, 
when recontacted after many months/years.” 
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Patient’s preferences not to be recontacted 
When asked hypothetically whether there might be reasons for HCPs to recontact patients even if 
patients indicate they do not want to (or they do not want their relevant family members to be 
recontacted), 67 genetic centres responded affirmatively. The most common reasons given were the 
availability of new relevant clinical information for the patient, or for a family member. In a few 
cases respondents stated that the law of their country requires them to recontact patients in the light 
of clinically relevant information irrespective of patient wishes, and other respondents reported that 
they used the primary care physician to facilitate the communication. 
 
“Our Ministry of Health has informed us that we may contact persons in certain conditions 
for example identification of a clear pathogenic mutation for a disease where treatment 
and/or prevention are possible” 
 
Eight of these respondents observed that patients might have changed their mind from the last 
contact with the clinic/time of consent:   
 
“If extremely important and clinically relevant information becomes available, patients 
should be notified, as their views might change over time (they might also not be aware of 
what they are rejecting)” 
 
Other justifications for recontacting patients irrespective of their preferences, were the implication 
of new information for future reproductive risk (for patients or relatives), and possible prenatal 
diagnosis, and the correction of analytical mistakes. 
A summary of the reasons is provided in table 3 (respondents could give more than one answer). 
 
[Table 3]  
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Among the 38 centres that responded they would always respect patient preferences not to be 
recontacted, 23 justified their position by referring to the patient’s right not to know, and 7 raised 
legal issues, (e.g. the fact that recontacting is forbidden by law in their country).  
 
“Our law generally forbids health care professionals from reaching out to people or their 
families. However, in unusual circumstances it can be done. If, for example, there was a new 
therapy that could effectively cure a serious disorder we would consider making an 
exception to the "do not contact" rule”. 
 
It is important to note that a considerable number of respondents commented that they had found it 
difficult to answer this question (irrespective of the answer given), mostly on the basis that they 
have never or rarely come across the situation of a patient expressing a desire not to be recontacted. 
This is in line with what was observed above (see section ‘Assessing and recording patient 
recontacting preferences’).   
 
HCPs view on the implementation of recontacting  
56centres responded that recontacting systems should be implemented. This position was common 
among many of the centres that stated they recontact routinely using established procedures. 39 
centres were not sure, and 10 centres answered negatively. 
 
Arguments in favour of implementing routine recontacting  
The main arguments for implementing routine recontacting systems were the improvement of the 
knowledge of the clinician, and the desire to provide the best service to the patients and families. 
Respondents’ also commented that recontacting is becoming more important because clinical 
whole-genome approaches deliver many more genetic variants for interpretation. Some pointed out 
13 
 
that new, relevant information (alongside reinterpretation of VUSs and correction of 
misleading/outdated information) could change management decisions for patients and offer 
opportunities for family screening, prevention, and new reproductive choices. Moreover, it was 
argued that recontacting could have a preventative value, reducing the cost of healthcare. 
Here are some illustrative quotations of the ‘pro’ arguments: 
 
‘[Recontacting offers] the possibility to play out a preventive medicine” 
 
“Genetics is advancing very fast. Every day we have new information, new techniques, 
better knowledge to interpret results, an old advice might be misleading”. 
 
“Otherwise [if we do not recontact] there will be unequal conditions for families/patients 
depending on the time they were tested/counselled”. 
 
However, some respondents expressed concerns about the implementation of recontacting, or the 
possibility of the development of recontacting guidelines. The main argument was that genetics 
services are long-established in certain European countries and less established in others and that 
the implementation of recontacting or the development of guidelines may further increase this 
disparity.   .  
 
“It [the implementation of recontacting] would be an ideal scenario. However, we should 
consider variable level of genetic service development in Europe. If such a system is 
recommended, it should be recommended only for services that have reached higher 
standards.” 
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Arguments against implementing routine recontacting  
The principal arguments against implementing routine recontacting systems were the lack of time, 
infrastructures, resources and staff to develop systematically recontacting procedures. 
Other common arguments against the implementation of routine recontacting systems were related 
to the patient’s right not to know, and concerns about causing anxiety and raising unrealistic 
expectations in patients, and for the possible legal consequences if such systems established a new 
standard of care without the additional resources required for it to be a sustainable activity.  
A summary of both the arguments in favour and against is reported in table 4. 
 
[Table 4] 
Here are some illustrative quotations of the ‘against’ arguments: 
 
“People may have forgotten they were counselled/tested and have lived in happy ignorance. 
They might become worried when confronted with a risk of developing a serious disease. 
They may think about relatives who died at a young age due to a genetic disease [for] which 
treatment/prevention are now possible/available.” 
 
“If you recontact regularly, this could raise unrealistic hopes that there would be better   
diagnosis and treatment.” 
 
Some respondents pointed out that HCPs working in ‘mainstream’ specialties, for instance 
paediatricians and cardiologists, are supposed to have a more on-going relationship with patients 
compared to the clinical geneticists. ‘Mainstream’ specialists, as well as primary care physicians, 
were seen by these respondents as having potentially more responsibility for recontacting patients.  
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Discussion 
The problem of defining recontacting  
The survey answers revealed a multiplicity of understandings of the term ‘recontacting’.  
In the introduction to our survey, as well as in the covering letter sent to the genetics centres with 
the link to the survey, we defined recontacting as contacting patients who have previously been 
discharged from a genetic service. Yet, some appeared to conflate routine follow-up program or 
even the post-test result counselling with recontacting. Some respondents referred to recontacting as 
being a process exclusively initiated by the clinician, others as something that can be initiated by 
either clinician or patient, while others suggested it could be initiated by the patient (or support 
groups) alone.   
It is important to reach an ‘operational definition’ that can be useful to clinical genetics centres, 
HCPs, and laboratories in different countries. It is also important to highlight that it can be 
particularly challenging for mainstream specialties to differentiate recontacting from follow-up. 
Moreover, mainstream specialties may not receive up-to-date information on DNA variant 
interpretation, as this happens predominantly in the genetics centres, or they may fail to contact the 
laboratory or the referring geneticist if new genetic information becomes available.  
As stated by one respondent: “Not all the genetic tests are requested by a clinical genetics 
department. As we mainstream more tests this work will be undertaken by non-geneticists and 
therefore the patients being tested will not be under our care.” 
 
Recontacting occurs in Europe, but not systematically 
Recontacting appeared to be important to respondents, even if only a minority of European centres 
routinely recontact. Many respondents who affirmed that they recontacted only occasionally 
highlighted that they would and should recontact more systematically, supporting the idea that 
recontacting can promote a better quality of care in clinical practice.   
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A significant number of respondents tended to ask patients if they would like to be recontacted (and 
record patient preferences). However, a majority of clinicians would hypothetically recontact 
patients or family members even if the patients asked not to be recontacted if this new information 
was clinically relevant. This response appears to be in line with the ESHG recommendations on the 
use of whole-genome sequencing in healthcare: “Patients’ claims to a right not to know do not 
automatically over-ride professional responsibilities when the patient’s own health or that of his or 
her close relatives is at stake” (p. 583) [23]. Even if current regulation of individual countries 
specifically recognises an individual’s right not to know diagnostic (genetic) information, in the 
majority of countries there are no rules that define the circumstances in which the clinicians should 
go against this right [7, 24].  
 
Without a professional consensus about whether and in what circumstances patients should be 
recontacted,  the decision whether or not to recontact the patients weighs on HCPs [4].  
Moreover, in some countries there may also be a tension between the law and the clinical ethics. 
 
Different recontacting procedures  
Recontacting procedures varied between different centres and countries.  Most involved the use of 
databases for recontacting purposes, but there was a considerable diversity in practices regarding 
the use of clinical genetics databases. This may be the result of historical and resource allocation 
differences.  
Some centres that stated they do not recontact patients, reported asking about patients’ recontacting 
preferences in the consent form. This suggest that these centres may be willing, but not able, to 
recontact – due to lack of staffing and resources; therefore, they currently limit themselves to only 
recording patients’ preferences.  
17 
 
Barriers to the development or implementation of recontacting procedures included lack of 
resources, concerns about potential negative psychological consequences of recontacting, unclear 
operational definitions of recontacting, policies that prevent HCPs from recontacting and 
difficulties in locating patients after their last contact. Any future recommendation about 
recontacting needs to consider these barriers. 
 
Implementation of recontacting systems 
56 centres answered that recontacting systems should be implemented. 
Among the reasons not to do so, the main issue was the lack of time, resources and staff.  This 
survey has also highlighted the different levels of development of European genetics centres in 
terms of procedures related to recontacting and the availability of staff/resources to recontact. This 
finding can in turn be explained by the fact that the development (and establishment) of the 
specialties of medical genetics and genetic counselling is highly variable across different European 
countries. In some countries, other professionals, medical and non-medical, often without an 
adequate training in genetics, evaluate and provide counselling to the patients. Furthermore, most 
clinical genetics services are multi-disciplinary. This means that any recontacting recommendations 
should not be prescriptive to a specific HCP group, but it is the organisational policy of each 
country as to which speciality should define the recontact process. However, it is also important that 
any recontacting recommendation contribute to a harmonisation of service standards rather than an 
amplification of discrepancies and service inequities within and between countries.  
 
The concern of recontacting patients inappropriately without respecting their autonomy and self-
determination was one of the major factors weighing against the implementation of recontacting, 
alongside with a concern for the psychological consequences of recontacting.  
As suggested by Carrieri et al. [25], a first step to mitigate these risks could be for HCPs to discuss 
with patients – routinely as part of the consent process for genetic testing or whenever patient data 
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are collected and recorded –the possibility of recontact, and assess patients expectations and 
preferences. Such discussion between HCP and patient would allow to clarify roles and 
expectations, and to minimise the risk of giving patients “false hope” or “false security”.  
The ESHG Guidelines for diagnostic next-generation sequencing state: “whenever major changes 
are made to the test, quality parameters have to be checked, and samples have to be re-run. The 
laboratory should define beforehand what kind of samples and the number of cases that have to be 
assayed whenever the method is updated or upgraded” [23]. Well-established procedures, such as a 
database shared between laboratories and clinicians, or systems to send updates from the laboratory 
to clinicians (realities already reported by some of our respondents) could help to trigger 
recontacting in those centres (the majority of the European genetic centres) that still do not benefit 
from a routine feedback from the laboratory, as suggested by some of the survey’s respondents. A 
question to consider now is whether the preventative value of reanalysing, reinterpretation and 
recontacting in practice reduce the overall cost of healthcare.  
 
Limitations of the study 
It has been problematic to identify all clinical genetic services across Europe. This is also due to a 
lack of policies in Europe that establish standards, and requirements necessary to define a clinical 
genetic centre.  
When it was possible to determine the response rate of the centres in answering the survey, this 
varied considerably among the different countries.  
Possibly because they did not want to be judged on the basis of their responses to the survey, some 
respondents did not report from which clinical centre they were writing and they only put the name 
of their country.  
It is also important to point out that the UK survey was administered between October 2014 and 
July 2015, around two years before the administration to the other European countries. Although we 
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think the results are comparable, we also recognise that in the two year period between the 
administrations of the surveys, clinical genetics technologies and procedures may have changed in 
ways that may be significant to recontacting, both in the UK and in the other European countries.  
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